5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- PROTEIN_SECRETION+0.500
- UV_RESPONSE_DN+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- TGF_BETA_SIGNALING+0.400
- ANDROGEN_RESPONSE+0.300
- MITOTIC_SPINDLE+0.300
- NOTCH_SIGNALING+0.300
- BILE_ACID_METABOLISM+0.200
- HEDGEHOG_SIGNALING+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- E2F_TARGETS-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
- MYC_TARGETS_V1-0.200
- ESTROGEN_RESPONSE_LATE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7416-01A-11R-2081-07 | — | — | 0.795 |
| 2 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.787 |
| 3 | TCGA-AR-A24M-01A-11R-A169-07 | — | B | 0.783 |
| 4 | TCGA-A8-A09A-01A-11R-A00Z-07 | — | B | 0.778 |
| 5 | TCGA-A8-A0AD-01A-11R-A056-07 | — | B | 0.774 |
| 6 | TCGA-E2-A1BC-01A-11R-A12P-07 | — | A | 0.766 |
| 7 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.765 |
| 8 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.760 |
| 9 | TCGA-E2-A15L-01A-11R-A12D-07 | — | B | 0.758 |
| 10 | TCGA-AN-A0XL-01A-11R-A10J-07 | — | A | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |